0.9651  0.035 (3.77%)		09-19 13:40
Open: 0.93 High: 1 Volume: 6,251		Pre. Close: 0.93 Low: 0.93 Market Cap: 35(M)

Short term
Mid term
Targets	6-month :	1.44	1-year :	1.7
Resists	First :	1.23	Second :	1.46
Pivot price	1.05
Supports	First :	0.87	Second :	0.72
MAs	MA(5) :	0.97	MA(20) :	1.09
	MA(100) :	1.17	MA(250) :	1.48
MACD	MACD :	-0.2	Signal :	-0.1
%K %D	K(14,3) :	14.1	D(3) :	17.7
RSI	RSI(14): 40.8
52-week	High :	15.44	Low :	0.81

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ESLA ] has closed above bottom band by 27.8%. Bollinger Bands are 2.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1 - 1.01	1.01 - 1.01
Low:	0.92 - 0.92	0.92 - 0.93
Close:	0.92 - 0.93	0.93 - 0.94

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Tue, 20 Aug 2024
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga

Wed, 14 Aug 2024
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member - Business Wire

Thu, 18 Jan 2024
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances - InvestorPlace

Tue, 19 Sep 2023
Estrella Immunopharma nears completion of SPAC listing - Bamboo Works

Wed, 09 Jun 2021
Unicycive Therapeutics (NASDAQ:UNCY) Stock Quotes, Forecast and News Summary - Benzinga

Tue, 06 Apr 2021
Achilles Therapeutics (NASDAQ:ACHL) Stock Quotes, Forecast and News Summary - Benzinga

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	36 (M)
Shares Float	10 (M)
Held by Insiders	71 (%)
Held by Institutions	0.3 (%)
Shares Short	20 (K)
Shares Short P.Month	40 (K)

EPS	-0.28
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.23
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-65 %
Return on Equity (ttm)	-278.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-16 (M)
Levered Free Cash Flow	-13 (M)

PE Ratio	-3.58
PEG Ratio	0
Price to Book value	4.19
Price to Sales	0
Price to Cash Flow	-2.22

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.